Generic Name and Formulations:
Fluorescein (as sodium) 100mg/mL (10%); soln for IV inj; preservative-free.
Alcon Laboratories, Inc.
Indications for FLUORESCITE:
Diagnostic angiography or angioscopy of the retina and iris vasculature.
Give by IV inj rapidly into the antecubital vein (normally 1mL/sec). 500mg (5mL). Highly sensitive imaging system (eg, scanning laser ophthalmoscope): reduce dose to 2mL.
Give by IV inj rapidly into the antecubital vein (normally 1mL/sec). 7.7mg/kg; max 500mg (5mL).
History of allergy. Bronchial asthma. Avoid extravasation; severe local tissue damage can result. Pregnancy. Nursing mothers: discontinue for ≥4 days after inj (pump and discard the milk during this period).
Skin and urine discoloration, nausea, vomiting, GI distress, hypersensitivity reactions, headache, thrombophlebitis; rare: cardiopulmonary reactions, convulsions, syncope.
Single use vial (5mL)—1
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Behavioral Weight Loss Interventions May Prevent Obesity
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Executive Function Predicts T1D Management Into Emerging Adulthood
- Intensive Blood Pressure Therapy Lowers Cardiovascular Risk in Diabetes
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age
- LVAD in Heart Failure Linked to Improved Glycemic Control
- Fundamental Institutional Change Is Needed to Eliminate Sexual Harassment
- Gestational Diabetes Tied to Subsequent Glucose Disorders
- Association Health Plans Can Help Small Businesses Offer Coverage